AstraZeneca plc, GlaxoSmithKline plc And Shire PLC Are Set For A Decade Of Rapid Growth

AstraZeneca plc (LON: AZN), GlaxoSmithKline plc (LON: GSK) and Shire PLC (LON: SHP) are set for rapid growth as sales explode.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The biotech industry has really entered a new phase of growth over the past few years. The value of research and development spending has surged, mergers have accelerated the development of experimental drugs, and the industry’s move away from ‘blockbuster’ treatments has increased the drive to find as many new treatments as possible. 

Over in the US, the Food and Drug Administration approved 41 new drugs for sale to the public last year, the highest number since 1996 and double the 10-year average. Meanwhile, the return on investment for R&D spending rose in 2014 for the first time since 2010, to 5.5%, up from 5.1% the previous year. 

It’s not just the wider industry that’s progressing. The UK three main pharmaceutical companies, AstraZeneca (LSE: AZN), GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP) are all at key stages in the development of their treatment pipelines. What’s more, all three are well placed to grow rapidly over the next decade. 

Pipelines are key 

Shire is planning to double its annual sales to $10bn by 2020 and the company plans to do this by concentrating on the development of rare disease treatments. A small but lucrative market.

Shire is now in a better position to chase this growth than it has ever been before, after receiving $1.6bn merger break fee from AbbVie. Still, even without this break fee, Shire is already making steady progress towards its long-term growth target. Third-quarter revenues rose almost a third to $1.6bn, beating estimates and hitting a record for the company. Excluding exceptional items, earnings per share rose to $2.10, or 129p for the nine months to 30 September, up 93% year on year.

Meanwhile, Astra has developed an industry-leading immuno-oncology portfolio with 13 clinical trials already under way. A further 16 trials are planned and a total of 14 potential new drugs are already in the process of Phase III testing or registration before sale. As many as 10 drug approvals are set for 2016. Astra has laid out an ambitious growth plan to deliver annual revenues of $45bn by 2023, up from reported revenues of just under $26bn during 2013.

Glaxo hasn’t set out a revenue target but the company is quickly adapting and changing its operations to put the group on a solid footing for growth. These deals include the asset swap with Novartis and a deal with Aspen Pharmacare Holdings, Africa’s biggest generic drug maker.

Deals have also been conducted in Asia to boost Glaxo’s presence within the region. What’s more, the company has around 40 new treatments under development at present. These new treatments should only add to the company’s growth.

Growing market 

Couple these new treatments with the projected growth in pharmaceutical spending over the next four to five years, and you can see how these companies are set to profit throughout the rest of the decade. 

For example, Chinese spending on healthcare, per capita, is expected to increase by over 75% during the next five years. Global spending on medicines alone is expected to increase 30% to $1.3trn over the same period. 

So overall, all the factors Shire, Glaxo and Astra need to achieve rapid growth are in place. It seems as if the sky is really the limit for these pharma companies. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »